Prostate cancer antigens are well described in the literature and different vaccination designs have been developed for the treatment of prostate cancer patients, including the cell-based vaccine sipuleucel-T (Provenge), which targets prostatic acid phosphatase (PAP).5 This evidence concerns the gene ACP3 and prostate carcinoma.